The progress in the development of DPI technology has boosted to use of sensitive drug molecules for lung diseases. However, delivery of these molecules from conventional DPI to the active site still posses a challenge with respect to deposition efficiency in the smaller airway region. At same time, serious systemic side effects of drugs have become a cause for concern. The development of  controlled release biodegradable lactose-free DPI can be responsible for maximum smaller airways deposition with least toxicity and improved patient compliance. The lactose-free DPI, further corroborates the great potential of anti-asthmatic drugs. This technology is expected to revolutionary approach towards enhanced therapeutic delivery of prospective drugs.